AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04970485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talking Matters
Description: Group-level, facilitator-led behavioral intervention for 14-19 year old Black and African American adolescents with an intergenerational component to reduce teen pregnancy, strengthen protective factors to improve optimal health, and increase access to trusted adults.
Study NCT03428737 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pressure support ventilation
Description: use of a pressure support level identical during the night to the pressure support level at the end of the day.
Study NCT02640885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley's cather ballon
Study NCT02318992 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota
Description: Fecal Microbiota will be delivered via colonoscopy.
Study NCT01832441 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intra thecal transplantation of autologous MNC
Description: Intra thecal inj.of 100 millions MNC in 3 doses at 7 days interval
Study NCT01840787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balafilcon A (8.6)
Description: To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
Study NCT01840787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balafilcon A (8.3)
Description: To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
Study NCT01840787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
Study NCT02196454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video with Male or Female Narrator
Description: Participants will watch an educational video about the quadrivalent HPV vaccine (Gardasil) narrated by either a male or female.
Study NCT04350554 — intervention group
Intervention type: OTHER
Intervention: Pregnancy
Description: To measure and characterize pregnancies and describe the clinical course during pregnancy
Study NCT04350554 — intervention group
Intervention type: OTHER
Intervention: Pregnancy
Description: To evaluate attitudes towards pregnancy (ie. planned pregnancy) and social support among women who become pregnant during the year 2020
Study NCT04174144 — intervention group
Intervention type: PROCEDURE
Intervention: Single-level TLIF
Description: Transforaminal interbody fusion approach, using polyaxial pedicle screws (Xia®, Stryker Spine, Allendale, NJ, USA), combined with a crescent-shaped interbody cage (T-Plus®, Pioneer Surgical Technology, Marquette, MI, USA), bilateral facet joint removal and laminectomy.
Study NCT00465725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picoplatin
Description: The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.
Study NCT02425709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Women will receive oral diclofenac 50 mg 1 hour before the procedure
Study NCT02425709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Women will receive oral tramadol 50 mg 1 hour before the procedure
Study NCT04030910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'LIFEView'
Description: A prototype audiovisual technology in development by Motitech AS.
Study NCT02131259 — intervention group
Intervention type: DRUG
Intervention: Afatinib dimaleate
Description: 20mg - 50mg
Study NCT00217399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00217399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given orally
Study NCT00093041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Weekly infusion
Study NCT00519753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)
Description: One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
Study NCT03397069 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Peribulbar block (control)
Description: The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture.
Study NCT03397069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peribulbar block(M1)
Description: The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture.
Study NCT02425709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women will receive an oral placebo 1 hour before the procedure
Study NCT03397069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peribulbar block(M2)
Description: The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture.
Study NCT03837223 — intervention group
Intervention type: DRUG
Intervention: GnRH agonist
Description: In High Responder patients (HR) (more than 18 follicles with diameter ≥ 12mm at ovulation induction), the trigger was obtained with triptorelin 0.2 mg sc. In this cohort if less of 18 oocytes were retrieved, patients were considered at intermediate risk of OHSS and fresh transfer was performed. An adequate support of the luteal phase was initiated: HCG 1500 IU / sc the day of the pick up + estradiol 4 mg + vaginal progesterone 400 mg daily (Rescue protocol).
Study NCT00910416 — intervention group
Intervention type: DRUG
Intervention: propofol, remifentanil, atracurium
Description: propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment
Study NCT00910416 — intervention group
Intervention type: DRUG
Intervention: propofol, remifentanil, atracurium, sevoflurane
Description: dosages are adapted according to clinician's judgment
Study NCT00910416 — intervention group
Intervention type: DEVICE
Intervention: EEG monitoring
Description: simultaneous monitoring with Bis and Neurosense
Study NCT04668456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: the drug administered either subtenon ot iv
Study NCT04668456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine 2%
Description: subtenon injection
Study NCT04668456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 2%
Description: subtenon injection
Study NCT04668456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacine 0.5%
Description: subtenon injection
Study NCT04668456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacine 0.5%
Description: subtenon injection
Study NCT04668456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: either subtenon or iv
Study NCT04668456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: either subtenon or iv
Study NCT03771664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: Administered as capsules.
Study NCT03771664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as capsules.
Study NCT03703284 — intervention group
Intervention type: OTHER
Intervention: Treatments to reduce intracranial pressure
Description: Drugs such as mannitol, glycerin fructose, etc and/or surgery
Study NCT02372955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: subjects will be randomly assigned to receive dapagliflozin 10 mg daily
Study NCT02372955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimpiride
Description: subjects will be randomly assigned to receive glimpiride 4 mg daily
Study NCT02726568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 375 mg Tid (1125 mg per day) until intracranial PD.
Study NCT02726568 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRS
Description: If intracranial PD, then the subjects get stereotatic radiosurgery （30Gy/3f) combined with Icotinib 375mg Tid.
Study NCT03913520 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Outcome research
Description: patients will undergo an evaluation of their outcome at 30 days postoperatively
Study NCT02032017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ceramic on ceramic couple
Description: All patients will get a standard total hip replacement (cementless hydroxyapatite coated cup and a titanium plasmasprayed stem) with a ceramic on ceramic (third generation biolox delta) couple. Preoperative leg length and offset are marked to reconstruct the preoperative leg length and to obtain the optimal offset.
Study NCT02032017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ceramic on ceramic couple
Description: All patients will get a standard total hip replacement (cementless hydroxyapatite coated cup and a titanium plasmasprayed stem) with a ceramic on ceramic (third generation biolox delta) couple. Preoperative leg length and offset are marked to reconstruct the preoperative leg length and to obtain the optimal offset.
Study NCT02032017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous assisted approach
Study NCT02032017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterolateral approach
Study NCT02032017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Both groups will receive usual care (UC) after surgery. This includes standard physiotherapy care consisting of mobilizing and strengthening techniques. All patients will receive a booklet containing information about the surgery, weight bearing after the surgery, and rehabilitation in general.
Study NCT02032017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Both groups will receive usual care (UC) after surgery. This includes standard physiotherapy care consisting of mobilizing and strengthening techniques. All patients will receive a booklet containing information about the surgery, weight bearing after the surgery, and rehabilitation in general.
Study NCT02454088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxylapatite and Triamcinolone acetate
Description: Combination Therapy Triamcinolone acetate and Calcium Hydroxylapatite
Study NCT02454088 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Hydroxylapatite and Placebo
Description: Calcium Hydroxylapatite and Placebo
Study NCT04284228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of NEXI-001 T Cells
Description: Procedure: A single IV infusion of NEXI-001 T Cells at Day 1 after Lymphodepletion(LD) Therapy.~At dose Level 1: 1.0 x 108 total viable T cells At dose Level 2: 2.0 x 108 total viable T cells~Procedure: Lymphodepletion: IV administration of fludarabine 30 mg/2 and cyclophosphamide 300 mg/m2 for 3 days.~lymphodepletion (LD) Therapy: Subjects will received bridging therapy agents during lymphodepletion for 3 consecutive days prior to receiving the NEXI-001 product~Drug: Fludarabine~Fludarabine infusion~Other Name: Fludarabine monophosphate~Drug: Cyclophosphamide~Cyclophosphamide infusion~Other Name: Cytoxan
Study NCT04254003 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DT1 Toric contact lenses
Description: Delefilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
Study NCT04254003 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AO1DfA contact lenses
Description: Senofilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
Study NCT00506363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed dye laser therapy
Description: Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
Study NCT00506363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed dye laser therapy
Description: Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
Study NCT00506363 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: pulsed dye laser therapy
Description: Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
Study NCT01686919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk-free
Description: milk-free diet during 8 preoperative weeks
Study NCT01469169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost (Ventavis inhaled, BAYQ6256)
Description: 2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)
Study NCT01371357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEST 1
Description: 2.4 g/day of guanidinoacetic acid
Study NCT01371357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEST 2
Description: 2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
Study NCT01371357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEST 3
Description: 2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
Study NCT01371357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEST 4
Description: 2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
Study NCT02933749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SctO2
Description: The non invasive cerebral oxymetry (INVOS-Covidien) has been used to measure cerebral oxygen saturation.
Study NCT02933749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS
Description: Bispectral index
Study NCT05791708 — intervention group
Intervention type: DRUG
Intervention: Sutimlimab
Description: CAD patients in Sutimlimab cohort must be treated according to routine clinical practice
Study NCT01544010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stage-Tailored Manual
Description: Manual with 5 sections for each Stage of change delivered at baseline
Study NCT01544010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stage Tailored Feedback Report
Description: Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.
Study NCT00655486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Subjects' dose of lacosamide may be increased or decreased as needed to maintain a subject's effective and tolerable dose during the study. Tablets are 50 mg or 100 mg each; Dose is 100 mg/day up to 800 mg/day administered twice daily throughout the study (up to 2 years).
Study NCT01057498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: RNS60, 4ml nebulized twice daily for 15 minutes.
Study NCT01057498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60 - single dose
Description: RNS60, single 4 ml dose nebulized for 15 minutes
Study NCT00402038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone
Description: Dose 1
Study NCT00402038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SC Placebo
Study NCT00295594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Immunosuppression
Study NCT00295594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Immunosuppression
Study NCT00858884 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
Description: All participating subjects (patients with and without neuropsychiatric SLE and healthy controls) will undergo clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
Study NCT01720173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalantercept
Description: Given SC
Study NCT01720173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04333927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week).
Study NCT04333927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation
Description: Patients in observation group will not receive any anti-cancer therapy.
Study NCT04333927 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal.
Study NCT04333927 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed.
Study NCT01509131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L PEG-CS plus bisacodyl
Description: Patients will be asked to take 2L of Lovolesse and bisacodyl (10-20 mg according to patient bowel habit)
Study NCT01509131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2L PEG-ASC
Description: Patients will asked to take PEG-ASC according to labeling instructions
Study NCT02497625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Therapeutic Alliance
Description: Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
Study NCT02497625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
Study NCT02497625 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Patients will not receive intervention in the first month in which they are enrolled. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.